World Health Organization Raises Alert Over Severe Lack of Weight-Loss Jabs
Fewer than one in 10 individuals that would benefit from weight-loss injections including Wegovy can access them, caution the WHO as it releases its first guidance on the medications.
Given over a billion individuals worldwide now obese, it is urging more widespread and fairer availability to these injectable treatments.
Per estimates, more than two billion are projected to be obese by 2030 unless action is taken.
"The latest guidance affirms that obesity is a chronic disease that can be managed with thorough and lifelong care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are major hurdles to universal access to the injections that can help people shift considerable weight, explains the organization.
Skinny Jab Scarcity
Despite the present best projected outlook, the production of such drugs might only reach around 100 million people – under 10% of eligible patients, as stated by the WHO.
The guideline encourages governments and firms to increase access, through measures like licensing agreements.
The intellectual property rights on semaglutide – the main component of a leading brand – is set to lapse in several countries in 2026.
The Way Weight-Loss Drugs Function
These medications mimick a natural hormone to reduce digestion speed, reduce hunger and increase satiety so people reduce food intake.
People usually begin shedding pounds after several weeks of beginning the once-weekly jabs.
Evidence indicates people may regain a significant portion after a year of halting the treatment, because their normal hunger return.
Being above a healthy weight raises your risk for developing medical conditions, like diabetes, heart disease, stroke, and specific malignancies.
Excess weight concerns people in countries worldwide and was linked to millions of fatalities worldwide in 2024, as per the health agency.
